Navigation Links
Lumenis(R) Introduces Four New Products & Delivery Devices at the 2008 American Academy of Ophthalmology Annual Meeting in Atlanta, Georgia USA
Date:11/6/2008

SANTA CLARA, Calif., Nov. 6 /PRNewswire/ -- Lumenis(R) Ltd. a global developer, manufacturer and marketer of laser, light-based and radiofrequency devices for ophthalmic, surgical and aesthetic applications, announced today that it will introduce four new ophthalmic lasers and delivery devices on November 8th at the American Academy of Ophthalmology (AAO) Annual Meeting in Atlanta, Georgia.

Dov Ofer, Lumenis' President and Chief Executive Officer stated: "Lumenis is proud to be yet again at the forefront of ophthalmic laser technology with the introduction of the Selecta(R) family of ophthalmic lasers, the Novus(R) Spectra(TM) Dual-Port Photocoagulator and the LumeProbe(TM) comprehensive family of premium endo photocoagulation laser probes. This industry-leading achievement stems from Lumenis' 40-year history of ophthalmic laser innovation. In 1970, we were the first company to introduce a laser in this field; since then, we have followed with a series of additional sight-preserving milestones, including the first laser photocoagulator, laser indirect ophthalmoscope, multicolor photocoagulator, photodynamic therapy laser, the revolutionary Selective Laser Trabeculoplasty (SLT) system and solid state multicolor laser."

"At this year's AAO Meeting, we simply continue this long-standing tradition as we proudly showcase the newest additions to our existing and already robust product portfolio of ophthalmic lasers - a new and complete set of ophthalmic laser solutions. Our Selecta family of lasers for the ophthalmic practice offers it all - from ultimate simplicity, to comprehensive choice of therapy with maximum flexibility. Our new laser delivery devices are specifically designed to provide superior performance, as well as improve physician comfort during procedures," said Dov Ofer.

"Today, Lumenis also further expands its capabilities in the Retina segment with the introduction of the LumeProbe product family," said Gideon (Gidi) Sturlesi, Corporate Vice President & acting General Manager of Lumenis Vision, the ophthalmic business unit of Lumenis. "Our newest line of premium ophthalmic endo-photocoagulation laser probes was designed with the retina specialist in mind, featuring advanced manufacturing practices, unique fiber polishing techniques and uncompromising quality assurance methodologies that deliver product performance & reliability second to none."

"Based on over 25 years of laser probes manufacturing expertise, the LumeProbe product family was designed to deliver laser energy in the safest and most efficient manner, guaranteeing optimal clinical outcome for all relevant viteroretinal indications," concluded Mr. Sturlesi.

New Product Introduction:

-- Selecta(R) Trio(TM) - The pinnacle product in the Selecta family, the

Lumenis Selecta Trio represents the next generation of multi-modality

products, offering retinal, cataract and advanced glaucoma therapies in

a single platform. The unit's integrated design, enhanced optics

and advanced laser cavity make the Trio one of the highest performing

laser products in the market - offering maximum flexibility with minimum

footprint.

-- Selecta(R) Duet(TM) - The Lumenis Selecta Duet(TM) represents the

industry's most advanced anterior-segment laser, combining the

advantages of YAG photodisruption capabilities along with the innovative

Selective Laser Trabeculoplasty (SLT) technology, which was developed

and brought to market by Lumenis. The system's fully integrated

design, enhanced optics and advanced laser cavity make the Duet one of

the best performing laser products in its segment. The Duet is also the

only upgradeable SLT and YAG combination Laser currently available in

the market - allowing our customers to further extend the unit's

capabilities by adding photocoagulation technology at any point in time.

-- Novus(R) Spectra(TM) Dual-Port - The Lumenis Novus Spectra is an

innovative photocoagulator with an extensive set of features that

deliver power and reliability with proprietary advancements in

diode-pumped solid-state technology. Next-generation DPSS technology

drives 2.5 W of power from the compact Novus Spectra system and an

active resonator temperature control ensures stable beam output and

system reliability. Versatile, efficient and compatible with a

wide-array of delivery devices, the dual-port Novus Spectra was designed

to provide optimal results in the operating room and outpatient clinic.

-- LumeProbe(TM) Endo Photocoagulation Laser Probes - a comprehensive and

robust set of premium ophthalmic endo photocoagulation laser probes for

OR usage. Based on over 25 years of laser probes manufacturing

expertise, the LumeProbe product family was designed to deliver laser

energy in the safest and most efficient manner, guaranteeing optimal

clinical outcome for all relevant viteroretinal indications.

Ophthalmologists attending the 2008 AAO meeting and seeking ultimate simplicity, maximum flexibility, comprehensive choice of therapy and complete operating room solutions will have access to Lumenis' new technology at AAO booth # 2021, November 8th through November 11th.

About the American Academy of Ophthalmology and 2008 Annual Meeting

The American Academy of Ophthalmology is the largest national membership association of ophthalmologists, medical doctors who provide comprehensive eye care, including medical, surgical and optical care. More than 90 percent of practicing U.S. ophthalmologists are Academy members, and the Academy has more than 7,000 international members. The Academy's 112th Annual Meeting from November 8 to 11 will be in Atlanta, GA, at the World Congress Center. The 2008 Annual Meeting program will highlight how technology advances are improving patient care. For more information about the AAO and Annual Meeting, log on to http://www.aao.org

About Lumenis

Lumenis is a leading medical device company with over 850 employees worldwide. The Company invests heavily in R&D and holds a leading position in the markets in which it serves. Lumenis has over 250 patents worldwide, over 75 FDA clearances, worldwide presence in over 100 countries, and an installed base of over 70,000 systems.

http://www.lumenis.com

Lumenis(R) is a registered trademark of Lumenis Ltd.

Contact:

Michelle Maydan

Director of Corporate Communications

1-866-569-0597

+972-4-959-9004

e-mail: mmaydan@lumenis.com


'/>"/>
SOURCE Lumenis Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Lumenis(R) Introduces the Newest Innovations in Fractional CO2 Laser Skin Therapy
2. Lumenis(R) Seeks Shareholder Approval of Proposed Class Action Settlement
3. Delta Dental of Illinois Introduces Smile Smart For Your Health
4. Highmark Blue Cross Blue Shield Introduces New Health Plan Comparison Tool for Consumers
5. Highmark Blue Shield Introduces New Health Plan Comparison Tool for Consumers
6. Sentillion Introduces Affordable Next Generation Healthcare Single Sign-On Solution Called expreSSO(TM)
7. GladRags Introduces the Moon Cup - An Environmentally-Sound and Safe Alternative to Disposable Feminine Hygiene Products!
8. Triveris Introduces Personal Health Record with Built-in Health Advisor
9. Verizon Introduces Broadband Video Call Center Link for Deaf or Hard-of-Hearing Customers in Mid-Atlantic Region
10. Mecklenburg EMS Introduces Most-Advanced Situational Training in America for Emergency Medical Personnel
11. Small Bone Innovations Introduces the Artelon(R) STT Spacer to Increase Treatment Options for Thumb Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension ... that it will receive two significant new grants to support its work to ... its 25th anniversary by recognizing patients, medical professionals and scientists for their work ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, ... treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including robotic ... osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It ...
(Date:6/24/2016)... ... 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join ... wage raise to $12 an hour by 2020 and then adjusting it yearly to increase ... of the minimum wage, assure the wage floor does not erode again, and make future ...
(Date:6/24/2016)... Georgia (PRWEB) , ... June 24, 2016 , ... ... awards today at the Clinical Decision Making in Emergency Medicine conference in Ponte ... have authored journal articles published in Emergency Medicine Practice and Pediatric ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative ... has initiated cultivation and processing operations at its production facility, and opened its ... Puradigm is the manufacturer of a complete system of proactive air and surface ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016 According to a ... (Standard Pen Needles, Safety Pen Needles), Needle Length (4mm, ... Hormone), Mode of Purchase (Retail, Non-Retail) - Trends & ... studies the market for the forecast period of 2016 ... 2.81 Billion by 2021 from USD 1.65 Billion in ...
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... 23, 2016 Any dentist who has made an ... current process. Many of them do not even offer this ... and high laboratory costs involved. And those who ARE able ... such a high cost that the majority of today,s patients ... Parsa Zadeh , founder of Dental Evolutions Inc. and ...
Breaking Medicine Technology: